Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBITDA (2020 - 2025)

Historic EBITDA for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$7.4 million.

  • GeneDx Holdings' EBITDA rose 519.55% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 10262.42%. This contributed to the annual value of -$51.9 million for FY2024, which is 7041.15% up from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' EBITDA is -$7.4 million, which was up 519.55% from $10.7 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBITDA high stood at $32.7 million for Q3 2021, and its period low was -$308.8 million during Q4 2022.
  • Moreover, its 5-year median value for EBITDA was -$40.2 million (2021), whereas its average is -$53.9 million.
  • As far as peak fluctuations go, GeneDx Holdings' EBITDA skyrocketed by 15781.33% in 2021, and later plummeted by 66834.89% in 2022.
  • Quarter analysis of 5 years shows GeneDx Holdings' EBITDA stood at -$40.2 million in 2021, then tumbled by 668.35% to -$308.8 million in 2022, then surged by 91.79% to -$25.3 million in 2023, then surged by 121.11% to $5.4 million in 2024, then crashed by 239.16% to -$7.4 million in 2025.
  • Its EBITDA stands at -$7.4 million for Q3 2025, versus $10.7 million for Q2 2025 and -$6.5 million for Q1 2025.